Aktuellt
SENASTE
Redeye notes that Egetis’ Q4 report presented SEK5.7m in revenues and SEK-83.9m in operating expenses, which closely correspond to our forecasts, albeit with a somewhat larger increase in OPEX than anticipated. This outcome indicates a stable business operation and the continued implementation of a commercial structure to prepare for the Emcitate launch. It is worth mentioning that the estimated timelines for regulatory submission with Emcitate (now scheduled for H2 2023) and study commencement with Aladote (now 2023) have been extended somewhat. At present, we do not foresee any significant adjustments to our valuation and will soon return with a more extensive take.
LÄS MER
